scholarly article | Q13442814 |
P50 | author | Ralph Weissleder | Q7288259 |
Jeroen van de Water | Q82762037 | ||
Randa Kasmieh | Q125261420 | ||
P2093 | author name string | Khalid Shah | |
Shawn D Hingtgen | |||
P2860 | cites work | Identification and characterization of a new member of the TNF family that induces apoptosis | Q24318423 |
The leading edge of stem cell therapeutics | Q28273636 | ||
Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. | Q35812718 | ||
Neural precursor cells and their role in neuro-oncology | Q36041769 | ||
Neural stem cells as novel cancer therapeutic vehicles | Q36477288 | ||
The promise of TRAIL--potential and risks of a novel anticancer therapy | Q36792997 | ||
Stem and progenitor cell-mediated tumor selective gene therapy | Q37120161 | ||
Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare | Q37122166 | ||
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy | Q37140126 | ||
Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). | Q37221909 | ||
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide | Q37356520 | ||
Optical and multimodality molecular imaging: insights into atherosclerosis | Q37440343 | ||
Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy | Q39245228 | ||
Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model | Q39988659 | ||
MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas | Q40073679 | ||
Fusion of Gaussia luciferase to an engineered anti-carcinoembryonic antigen (CEA) antibody for in vivo optical imaging | Q40118072 | ||
Bifunctional antibody-Renilla luciferase fusion protein for in vivo optical detection of tumors | Q40249070 | ||
Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines | Q40432328 | ||
Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. | Q40476541 | ||
Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells | Q40490888 | ||
Optical bioluminescence and positron emission tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice | Q40662328 | ||
Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis | Q40860890 | ||
Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo. | Q43713225 | ||
Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy | Q44198636 | ||
Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo | Q44611172 | ||
Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety | Q46661382 | ||
Prospects for stem cell-based therapy | Q47893771 | ||
Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. | Q49011276 | ||
Construction and characterization of two versions of bifunctional EGFP-sTRAIL fusion proteins. | Q50677686 | ||
In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. | Q55471304 | ||
Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics | Q77710566 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 832-841 | |
P577 | publication date | 2010-04-01 | |
P1433 | published in | Stem Cells | Q15724411 |
P1476 | title | A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy | |
P478 | volume | 28 |
Q34341900 | A first-generation multi-functional cytokine for simultaneous optical tracking and tumor therapy |
Q33753135 | Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors |
Q89936443 | Developing Implantable Scaffolds to Enhance Neural Stem Cell Therapy for Post-Operative Glioblastoma |
Q30843565 | Electrospun nanofibrous scaffolds increase the efficacy of stem cell-mediated therapy of surgically resected glioblastoma |
Q36695971 | Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas |
Q36082553 | Exogenous marker-engineered mesenchymal stem cells detect cancer and metastases in a simple blood assay. |
Q36684365 | Fibrin matrices enhance the transplant and efficacy of cytotoxic stem cell therapy for post-surgical cancer. |
Q94660275 | Generation and Profiling of Tumor-Homing Induced Neural Stem Cells from the Skin of Cancer Patients |
Q36085406 | In vivo tracking of mesechymal stem cells using fluorescent nanoparticles in an osteochondral repair model |
Q57640952 | Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection |
Q36092724 | Mesenchymal stem cells engineered for cancer therapy |
Q26799013 | Mesenchymal stem cells secretome as a modulator of the neurogenic niche: basic insights and therapeutic opportunities |
Q37938466 | Migration and fate of therapeutic stem cells in different brain disease models. |
Q33704489 | Neural stem cell therapy for cancer |
Q36913828 | Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors |
Q36543537 | Real-time multi-modality imaging of glioblastoma tumor resection and recurrence. |
Q47901080 | Space Invaders: Brain Tumor Exploitation of the Stem Cell Niche |
Q37433463 | TRAIL on trial: preclinical advances in cancer therapy |
Q36339837 | Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. |
Q27333831 | Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma. |
Q48329121 | Tumor-homing cytotoxic human induced neural stem cells for cancer therapy. |
Search more.